FDA Chronic Fatigue Guidance Takes Flexible Stand On Patient-Reported Outcomes
This article was originally published in The Pink Sheet Daily
Executive Summary
Clinical trial efficacy endpoints for investigational CFS/ME drugs should include patient-reported symptoms, but FDA is open to the use of instruments evaluated in other populations for this purpose, agency says in a new draft guidance.